Is Themis Medicare overvalued or undervalued?
As of June 26, 2025, Themis Medicare is fairly valued with a PE ratio of 40.65 and an EV to EBITDA of 26.15, but has underperformed the Sensex with a 49.93% decline year-to-date, while its PEG ratio of 0.00 suggests no growth expectations compared to more attractively valued peers like Cipla and Dr Reddy's Labs.
As of 26 June 2025, Themis Medicare's valuation grade has moved from expensive to fair, indicating a more favorable outlook for the company. The stock is currently fairly valued. Key ratios include a PE ratio of 40.65, an EV to EBITDA of 26.15, and a ROCE of 8.28%. In comparison to peers, Themis Medicare's PE ratio is higher than Sun Pharma's 35.03 but lower than Divi's Lab's significantly high 79.95. Additionally, while Themis's PEG ratio stands at 0.00, indicating no growth expectations priced in, competitors like Cipla and Dr Reddy's Labs are valued more attractively at 23.19 and 19.48 respectively. Notably, Themis Medicare has underperformed against the Sensex year-to-date, with a decline of 49.93% compared to the Sensex's gain of 7.19%.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
